Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7580168 | 0.78 | BCL2 (0.33) | CRHR1 | |
| SCHEMBL7865778 | 0.72 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2CRHR1 | |
| SCHEMBL7583915 | 0.70 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL7866024 | 0.68 | OPRM1 (0.35) | CRHR1 | |
| SCHEMBL7589128 | 0.68 | BCL2 (0.32) | CRHR1 | |
| SCHEMBL7658816 | 0.67 | HTT (0.44) | ALDH1A1LMNASMN1; SMN2KMT2APOLB | |
| SCHEMBL8977472 | 0.64 | ALDH1A1 (0.45) | CFBALDH1A1SPHK1SPHK2SMN1; SMN2 | |
| SCHEMBL6436481 | 0.64 | ALDH1A1 (0.45) | CFBALDH1A1SPHK1SPHK2SMN1; SMN2 | |
| SCHEMBL14155734 | 0.64 | ALDH1A1 (0.45) | CFBALDH1A1SPHK1SPHK2SMN1; SMN2 | |
| SCHEMBL1923804 | 0.62 | ALDH1A1 (0.39) | CFBALDH1A1SMN1; SMN2CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0941223-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-15 | — | — | EP | claimed |
| WO-1998021200-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-05-22 | — | — | WO | claimed |
| US-6469041-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6300360-B1 | FOR THERAPY OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6127399-A | TREATING POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5973152-A | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | CRH, CRHR1, CRHR2 | CFB 1205/4885ALDH1A1 1975/4885LMNA 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.